ArticleCurrent medicinal chemistry2026
Pharmacovigilance of SSRIs in Children and Adolescents with Depression: Disproportionality Analysis of Serotonin Adverse Events Using the FAERS Database.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDepression in minors is a growing global health concern with limited pharmacological options. This study evaluated the safety profiles of four selective serotonin reuptake inhibitors (SSRIs)-fluoxetine, sertraline, escitalopram, and fluvoxamine- in children and adolescents, focusing on serious adverse events (SAEs).
methodsPediatric adverse event reports from the FAERS database (Q1 2004-Q1 2025) were analyzed. Only reports listing the study drugs as Primary Suspect were included; duplicates were removed. Events were coded using MedDRA 26.1 and analyzed at system organ class (SOC) and preferred term (PT) levels. Disproportionality analyses used reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma-Poisson shrinker (MGPS), with Bayesian shrinkage (EBGM05) applied to low-frequency signals.
resultsPsychiatric events, including suicidal ideation, suicide attempts, and self-injury, showed the most consistent signals. Fluoxetine and sertraline had broad profiles; escitalopram showed higher disproportionality for psychiatric, cardiac, and perinatal events; fluvoxamine showed elevated signals for impulsive behaviors and rare systemic events. Neurological events, such as serotonin syndrome and tremor, were consistently reported; congenital and perinatal signals had limited statistical stability. DISCUSSION: SSRIs share common psychiatric AE signals in minors, but differences in strength and distribution likely reflect real-world exposure, metabolic pathways, and structural properties rather than causal differences.
conclusionFAERS-based pharmacovigilance provides a comparative overview of SSRI safety, with multi-algorithm assessment and Bayesian shrinkage enhancing low-frequency signal reliability, informing safer SSRI use and guiding future studies integrating pharmacokinetics and pharmacogenomics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.